
USD
+$0.00
(+0.00%
)At Close (As of Oct 24, 2025)
$25.19B
Market Cap
-
P/E Ratio
-1.66
EPS
$129.27
52 Week High
$81.20
52 Week Low
HEALTHCARE
Sector
| Field | Value (EUR) |
|---|---|
| Gross Profit | $2.2B |
| Total Revenue | $2.8B |
| Cost Of Revenue | $541M |
| Costof Goods And Services Sold | $541M |
| Operating Income | -$1.3B |
| Selling General And Administrative | $531M |
| Research And Development | $2.3B |
| Operating Expenses | $3.5B |
| Investment Income Net | - |
| Net Interest Income | $425M |
| Interest Income | $438M |
| Interest Expense | $13M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $298M |
| Income Before Tax | -$678M |
| Income Tax Expense | -$12M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$665M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$665M |
| Ebitda | -$367M |
| Net Income | -$665M |
| Field | Value (EUR) |
|---|---|
| Total Assets | $23B |
| Total Current Assets | $19B |
| Cash And Cash Equivalents At Carrying Value | $9.8B |
| Cash And Short Term Investments | $9.8B |
| Inventory | $283M |
| Current Net Receivables | $1.5B |
| Total Non Current Assets | $3.7B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $790M |
| Intangible Assets Excluding Goodwill | $790M |
| Goodwill | $381M |
| Investments | - |
| Long Term Investments | $1.3B |
| Short Term Investments | $7B |
| Other Current Assets | $213M |
| Other Non Current Assets | - |
| Total Liabilities | $3.1B |
| Total Current Liabilities | $2.5B |
| Current Accounts Payable | $427M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $40M |
| Total Non Current Liabilities | $595M |
| Capital Lease Obligations | - |
| Long Term Debt | $215M |
| Current Long Term Debt | $40M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $254M |
| Other Current Liabilities | $1.8B |
| Other Non Current Liabilities | $134M |
| Total Shareholder Equity | $19B |
| Treasury Stock | - |
| Retained Earnings | $19B |
| Common Stock | $249M |
| Common Stock Shares Outstanding | $240M |
| Field | Value (EUR) |
|---|---|
| Operating Cashflow | $208M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $298M |
| Capital Expenditures | $452M |
| Change In Receivables | - |
| Change In Inventory | $75M |
| Profit Loss | - |
| Cashflow From Investment | -$2.1B |
| Cashflow From Financing | -$46M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $0 |
| Dividend Payout Common Stock | $0 |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$665M |
| Field | Value (EUR) |
|---|---|
| Gross Profit | $2.2B |
| Total Revenue | $2.8B |
| Cost Of Revenue | $541M |
| Costof Goods And Services Sold | $541M |
| Operating Income | -$1.3B |
| Selling General And Administrative | $531M |
| Research And Development | $2.3B |
| Operating Expenses | $3.5B |
| Investment Income Net | - |
| Net Interest Income | $425M |
| Interest Income | $438M |
| Interest Expense | $13M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $298M |
| Income Before Tax | -$678M |
| Income Tax Expense | -$12M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$665M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$665M |
| Ebitda | -$367M |
| Net Income | -$665M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2022-06-02 |
| Declaration Date | None |
| Record Date | None |
| Payment Date | None |
| Amount | 2.111 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
BioNTech SE is a leading biotechnology company headquartered in Mainz, Germany, dedicated to the development and commercialization of innovative immunotherapies targeting cancer and infectious diseases. Known for its rapid advancement of a groundbreaking COVID-19 vaccine in collaboration with Pfizer, BioNTech boasts a robust pipeline focused on personalized cancer treatments and cutting-edge mRNA-based therapeutics. The company leverages its expertise in mRNA technology to pioneer precision medicine solutions that aim to meet significant unmet medical needs worldwide. With a strong commitment to scientific research and strategic partnerships, BioNTech is well-positioned to maintain its leadership in the dynamic biotechnology landscape.